Christopher Shao-Wei, Fei Kou, and Lynn Wang, NTD
In China, a generic drug can be approved for market launchbefore the original brand name drug patent expires. Although the
Bolarexemption is stipulated in Chinese patent law, in this case, the “artificialact of infringement” principle is still not
The rest of this document is only available to i-law.com online
If you are already a subscriber, please enter your details below to log in.